VORICONAZOLE FOR PROVEN AND PROBABLE ASPERGILLOSIS - COMPANY FILE DATA

number

Overall success

• BMT

• GvHD

• Relapsing hematologic malignancy

• Prolonged neutropenia

• No risk factor known

340

41% (n=208)

22% (n=23)

31% (n=39)

17% (n=6)

34% (n=29)

50% (n=117)

Previous slide

Next slide

Back to first slide

View graphic version